Nabriva Therapeutics (NBRVF)
OTHER OTC:NBRVF
US Market
Holding NBRVF?
Track your performance easily

Nabriva Therapeutics (NBRVF) Stock Price & Analysis

1,019 Followers

NBRVF Stock Chart & Stats


Financials

Annual

Ownership Overview

<0.01%100.00%
Insiders
<0.01% Other Institutional Investors
100.00% Public Companies and
Individual Investors

Risk Analysis

Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy

NBRVF FAQ

What was Nabriva Therapeutics’s price range in the past 12 months?
Nabriva Therapeutics lowest stock price was $0.13 and its highest was $0.50 in the past 12 months.
    What is Nabriva Therapeutics’s market cap?
    Currently, no data Available
    When is Nabriva Therapeutics’s upcoming earnings report date?
    Nabriva Therapeutics’s upcoming earnings report date is Nov 09, 2023 which is 370 days ago.
      How were Nabriva Therapeutics’s earnings last quarter?
      Currently, no data Available
      Is Nabriva Therapeutics overvalued?
      According to Wall Street analysts Nabriva Therapeutics’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
        Does Nabriva Therapeutics pay dividends?
        Nabriva Therapeutics does not currently pay dividends.
        What is Nabriva Therapeutics’s EPS estimate?
        Nabriva Therapeutics’s EPS estimate for its next earnings report is not yet available.
        How many shares outstanding does Nabriva Therapeutics have?
        Nabriva Therapeutics has 3,230,837 shares outstanding.
          What happened to Nabriva Therapeutics’s price movement after its last earnings report?
          Currently, no data Available
          Which hedge fund is a major shareholder of Nabriva Therapeutics?
          Among the largest hedge funds holding Nabriva Therapeutics’s share is Aisling Capital Management LP. It holds Nabriva Therapeutics’s shares valued at N/A.
            ---

            Nabriva Therapeutics Stock Smart Score

            Company Description

            Nabriva Therapeutics

            Nabriva Therapeutics Plc is a clinical stage biopharmaceutical company, which engages in the research and development of novel antibiotics to treat serious infections. Its product pipeline includes Lefamulin, CONTEPO, and BC-7013. The company was founded in October 2005 and is headquartered in Dublin, Ireland.
            ---
            Similar Stocks
            Company
            Price & Change
            Follow
            Aclaris Therapeutics
            Akari Therapeutics
            ANI Pharmaceuticals
            FibroGen
            Popular Stocks
            ---
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis